Evidence map›Paper›PMID 42111024›Full record

ArticleNeuro-oncology practice2026

Seizure prophylaxis in glioma surgery (SPRING): A multi-center, unblinded, randomized trial.

Michael D Jenkinson, Helen Bulbeck, Jackie Burns, Alasdair G Rooney, Richard Dobbie, Jade Carruthers, Sarah Lessels, Rachael Watson, Ciara Gribben, Tomos Robinson and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT.Health technology assessment (Winchester, England) · 2026
    Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Michael D JenkinsonInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool (M.D.J., A.G.M.).ORCID https://orcid.org/0000-0003-4587-2139
Helen BulbeckDepartment of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool (M.D.J.).ORCID https://orcid.org/0000-0002-6775-5251
Jackie Burnsbrainstrust-the Brain Cancer People, Cowes, Isle of Wight (H.B.).
Alasdair G RooneyScottish Clinical Trials Research Unit, Public Health Scotland, Edinburgh (J.B., R.D., J.C., S.L., R.W., C.G.).
Richard Dobbiebrainstrust-the Brain Cancer People, Cowes, Isle of Wight (H.B.).
Jade Carruthersbrainstrust-the Brain Cancer People, Cowes, Isle of Wight (H.B.).
Sarah Lesselsbrainstrust-the Brain Cancer People, Cowes, Isle of Wight (H.B.).
Rachael Watsonbrainstrust-the Brain Cancer People, Cowes, Isle of Wight (H.B.).
Ciara Gribbenbrainstrust-the Brain Cancer People, Cowes, Isle of Wight (H.B.).
Tomos RobinsonCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh (A.G.R., G.T.).
Luke ValeCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh (A.G.R., G.T.).
Gerard ThompsonScottish Clinical Trials Research Unit, Public Health Scotland, Edinburgh (J.B., R.D., J.C., S.L., R.W., C.G.).
Sara C ErridgePopulation Health Sciences Institute, Newcastle University, Newcastle upon Tyne (T.R., L.V.).
Colin WattsEdinburgh Cancer Centre, NHS Lothian, Edinburgh (S.C.E.).ORCID https://orcid.org/0000-0003-3531-8791
Anthony G MarsonInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool (M.D.J., A.G.M.).
Robin GrantDepartment of Neurology NHS Lothian, Edinburgh (R.G.).ORCID https://orcid.org/0000-0003-2597-9510
SPRING study Collaborators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: 50%-80% of glioma patients will have seizures. Guidelines recommend against prophylactic anti-seizure medication, but levetiracetam is frequently prescribed. Our aim was to determine the effectiveness of 12-month prophylactic levetiracetam at reducing seizure risk. Methods: Seizure-naïve patients undergoing glioma surgery were randomized (1:1) to 12-month levetiracetam or no prophylaxis and followed until death or a maximum of 18-months. The primary outcome was 1-year risk of first seizure. Patients who died within 12 months of randomization without experiencing a seizure were excluded from the primary outcome analysis. Target accrual was 804 participants. The trial was registered (ISRCTN 49474281 and EudraCT 2018-001312-30). Results: Between October 10, 2019 and August 30, 2022, 96 patients, from 24 to 79 years of age, were randomized to levetiracetam ( Conclusions: The seizure prophylaxis in glioma surgery (SPRING) trial provides no evidence of a difference between levetiracetam and no prophylaxis in the 12-month seizure risk in patients undergoing glioma surgery, but the study was underpowered. The role of prophylactic anti-seizure medication remains undefined.

Indexed as

clinical trialgliomalevetiracetamprophylaxisseizure

Identifiers

PMID42111024
PMCPMC13153692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.